BeiGene, Ltd. (BGNE) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Cambridge, MA, United States. El CEO actual es John V. Oyler.
BGNE tiene fecha de IPO 2016-02-03, 10,600 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $20.21B.
BeiGene, Ltd. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for cancer treatment globally. The company's commercial portfolio includes approved drugs such as BRUKINSA for mantle cell lymphoma, Tislelizumab for Hodgkin's lymphoma, and several other therapies for hematologic and solid tumors, complemented by a robust pipeline of clinical-stage candidates targeting various cancer types through innovative mechanisms including BTK inhibitors, PD-1/PD-L1 antibodies, kinase inhibitors, and specialized immunotherapies. BeiGene maintains strategic partnerships with leading pharmaceutical companies including Amgen, Novartis, and Bristol Myers Squibb to strengthen its research and commercialization capabilities. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company operates a comprehensive oncology platform serving patients worldwide.
